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ABSTRACT
Benzopyrones are the club of compounds that can be coumarins or flavonoids. The hydroxyl derivatives of coumarins such as 4-hydroxycoumarins 
and 7-hydroxycoumarins have extensive biological activities which have employed for the synthesis of miscellaneous coumarin derivatives. These 
derivatives have exhibited impressive pharmacological and physiological activities such as anticoagulant, antibacterial, antiviral, antitumor, 
bactericidal, fungicidal, anti-inflammatory agents, and anti-HIV activity. This review comprised pharmacokinetic studies, including absorption, 
distribution, and metabolism of coumarin analogs along with toxicological studies. The studies of coumarins and their derivatives exhibiting immense 
pharmacological activity are also summarized in the current study.
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INTRODUCTION
Multitudinous, diverse and novel chemical analogs with the splendid 
potential to be used as drug have been obtained from natural sources. 
However, designing and synthesizing a novel drug analog using 
combinatorial chemistry along with high-throughput screening is 
still a challenging task for scientists. The word coumarins symbolize 
to “coumarou,” acknowledged as the Tonka bean (Dipteryx odorata 
wild, Fabaceae), from which coumarin itself was isolated in 1820 [1]. 
Coumarin is affiliated to benzopyrone, which consist of a benzene ring 
fused to a pyrone ring [2,3]. The benzopyrones can be sub-classified 
into the benzo-α-pyrones to which the coumarins belong and the 
benzo-γ-pyrones to which the flavonoids belong [4-6] (Fig. 1).
CATEGORIZATION OF COUMARINS
Murray et al. [11] classified coumarins into four sub-classes as 
represented in Table 1.
PHARMACOKINETICS PORTRAIT OF COUMARINS
Absorption and distribution
Coumarin in humans, on oral administration is rapidly absorbed 
from the gastrointestinal tract and distributed throughout the body. 
Coumarin and 7-hydroxycoumarin both are less soluble in water 
(0.22 and 0.031%, respectively) and it expressed of limited in vivo 
bioavailability. However, coumarin and 7-hydroxycoumarin have 
elevated partition coefficients in aqueous solution as 21.5 and 10.4%, 
respectively, which is agreeable for the rapid absorption of compounds. 
It also conjugates the fact that being nonpolar in nature, it can cross 
lipid bilayers easily by passive diffusion [9-14].
Coumarin is metabolized by the liver in the first pass with only between 
2% and 6%, reaching the systemic circulation intact [9]. The low 
bioavailability of coumarin, in addition to its short half-life (1.02 h 
peroral vs. 0.8 h intravenous) has brought into question its importance 
in vivo and it is now acknowledged that coumarin is a prodrug, 
with 7-hydroxycoumarin being the compound of main therapeutic 
importance [8]. Ritschel et al. [15] proclaimed that 35% of coumarin 
and 47% of 7-hydroxycoumarin binds to plasma proteins. Therefore, 
the bioavailability of the compounds should not be problematic since 
the proportions that bound were well below the accepted critical value 
of 80% binding. The pharmacokinetics profiles of coumarin have been 
studied in rats, dogs, gerbils, rhesus monkeys, and humans [9]. Recently, 
numerous immunoanalytical approaches including enzyme-linked 
immunosorbent assay-based methods have been employed for the 
detection of coumarin and 7-hydroxycoumarin in urine [16]. Antibody-
based biosensors have also been utilized with either electrochemistry 
or surface plasmon resonance (BIAcore) to detect coumarin analogs in 
many matrices [17,18].
Metabolism
Multiple pharmacologists have accomplished their research in studying 
the metabolic fate of coumarins [9,19,20]. This study is essential to 
understand the possible coumarin-induced toxicity on metabolism [14]. 
Initially, coumarin is metabolized by cytochrome (CYP) P450-linked 
mono-oxygenase enzyme (CYP2A6) system in liver microsomes, 
leading to hydroxylation to form 7-hydroxycoumarin. Thereafter, 
phase II conjugation reaction resulting in a glucuronide conjugation 
is associated with 7-hydroxycoumarin. The 7-hydroxylase activity is 
remarkably high in human liver microsomes compared with its activity 
in the livers of other mammals. The activity of coumarin 3-hydroxylase 
is high in rodent microsomes but is absent in human microsomes.
It is noteworthy that coumarin can be metabolized by hydroxylation 
at all six possible positions around the carbons. However, metabolic 
product in the form of 7-hydroxycoumarin has attained recognition 
since it is produced in humans and can be easily analyzed. The 
hydroxylation at carbon three results in further metabolism through 
ring opening, yielding two more products, o-hydroxyphenyllactic acid 
and o-hydroxyphenylacetic acid [9,14,21].
It is imperative to mention that genetic and environmental factors 
result in changing the expression of CYP2A6 between humans, which 
causes interindividual variations in the metabolism of coumarins [21]. 
Metabolic studies in humans include the administration of drugs 
orally followed by urine collection and analysis with or without timed 
fractionation [7,22]. The measurement of urinary 7-hydroxycoumarin 
following an oral dose of coumarin is a vital biomarker of human hepatic 
CYP2A6, the CYP P-450 isoform, which is responsible for the generation 
of 7-hydroxycoumarin in liver [14]. It is noticeable to mention that some 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30635
Review Article
28
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 27-38
 Gupta et al. 
humans metabolize a significant proportion of coumarins in their body 
through 3,4-epoxidation pathway. CYP2A subfamily in humans has three 
genes, of which CYP2A6 is essential as the other two, namely CYP2A7 
and CYP2A13 are either inactive or sometimes expressed improperly 
in the liver. CYP2A6 codes the enzyme, catalyzing the generation of 
7-hydroxycoumarin (about 10% of total P450) [26]. Recently, CYP2A6 
has been reported to be polymorphically expressed in the human 
liver and involved in the metabolism of nicotine and cotinine. Hence, 
the various studies proclaimed that some drugs, including various 
coumarin analogs are metabolized chiefly by CYP2A6. Many substrates 
and inhibitors currently known to be metabolized by or interfered 
with CYP2A6 in vitro and in vivo have been illustrated by Pelkonen 
et al. [26,27]. Nowadays, spectrofluorometry, high-performance liquid 
chromatography and capillary electrophoresis are employed for the 
analysis of many metabolic products [23-25]. Recent in vitro studies 
include tissue slices, hepatocytes, subcellular fractions, and purified, 
and cDNA-expressed enzymes [9]. The data for various coumarin dose 
levels and collection periods are tabulated in Table 2.
Toxicological studies
Since 1954, the Food and Drug Administration classified coumarins as 
toxic due to its possibility to produce liver tumor in rats [28] and banned 
foods containing coumarin [12]. National Institute for Occupational 
Safety and Health referred coumarins as a carcinogenic agent. However, 
caution must be taken in extrapolating this information to human 
situations. Various other tests (Ames, micronucleus) have reported 
that coumarin and its metabolites are non-mutagenic [6]. Preliminary 
examinations of early studies showed that coumarin was a toxin, but the 
fact that rat is a poor model compared to humans in metabolism [28,29]. 
Since now, multiple studies have been accomplished to understand the 
acute, chronic and carcinogenic effects of coumarin in the rat and mouse. 
In these studies, hepatic biochemical and morphological changes in rats 
have been analyzed for various periods of coumarin administration 
(1 week–2 years). Depending on the dose administered, coumarin 
treatment results in an increase in relative weight and changes in 
various hepatic biochemical parameters. Single oral doses of coumarin 
have been shown to produce liver necrosis and increase plasma 
transaminase activities in DBA/2 strain mice [9]. In contrast, studies 
involving baboons, Syrian hamsters and certain mice strains were 
resistant to acute coumarin-induced hepatotoxicity. Species differences 
in coumarin-induced toxicity in vitro have been analyzed in cultured 
Table 1: Classification of coumarins
Classification Features Examples
Simple Hydroxylated, alkoxylated or alkylated on benzene ring
Furanocoumarins 5-membered furan ring attached to benzene ring. Linear or Angular
Pyranocoumarins 6-membered pyran ring attached to benzene ring. Linear or Angular
Pyrone-substituted Coumarins Substitution on pyrone ring, often at 3-C or 4-C positions
Table 2: Extent of coumarin metabolism to 7‑hydroxycoumarin in various species
Species Dose (mg/kg) Collection time (h) Urinary 7‑HC (% of Dose)
Rat 100, oral 890 or 120 0.4
Mouse 21, i.p. 22 25
Syrian hamster 200, oral 24 5
Squirrel monkey 200, oral 24 1
Baboon 200, oral 24 60
Human 200 mg/subject, oral 24 b79 (range 68–92)
200 mg/subject, oral 24 c63 (range 40–97)
bShilling et al. [19], cEgan et al. [7]
Fig. 1: The chemical structures of benzopyrone subclasses 
(benzo-α-pyrone) [a], and (benzo-γ-pyrone) [b]
ba
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hepatocytes. These studies provide evidence for species differences in 
coumarin-induced toxicity in vitro. The relative resistance of human 
and cynomolgus monkey liver slices and/or hepatocytes to coumarin 
toxicity correlates with coumarin 7-hydroxylation, the major pathway of 
coumarin metabolism in these species, being a detoxification pathway 
of coumarin metabolism. However, while coumarin-7-hydroxylation 
pathway is a detoxification pathway this does not appear to be the only 
reason for the resistance of a species to coumarin-induced toxicity. This 
may result in enterohepatic circulation enhancing the exposure of liver 
cells to toxic coumarin metabolites. Species such as Syrian hamster, 
baboon, and humans excrete coumarin metabolites primarily in the 
urine. Low level coumarin from diet and fragrances used in cosmetic 
products would not be estimated to produce any hepatotoxicity even in 
individuals with lack of 7-hydroxylase activity [9,14].
COUMARINS AS ACTIVE BIOLOGICAL AGENTS
Antibacterial activity
Lin et al. [30] synthesized 4-hydroxy and 7-hydroxycoumarin 
derivatives by reaction with activated aziridines analog to produce a 
series of ring-opened products as represented in Fig. 2. 3-carboxy 
coumarin amide dimer derivatives were also synthesized by reacting 
aliphatic alkyl amines and alkyl diamines with benzotriazol-1-
yl-oxytripyrrolidinophosphonium hexafluorophosphate and N, 
N-Diisopropylethylamine. Some of these compounds and dimer 
products exhibited antibacterial potential investigated by modified 
micro-plate antibiotic susceptibility test.
Hu et al. [31] synthesized imidazole bearing coumarin analogs in 
their structure and inspected for antibacterial activities against 
Escherichia coli, Staphylococcus aureus, Streptococcus agalactiae, 
and Flavobacterium cloumnare. The results revealed that compound 13 
and 18 were excellent antimicrobial agents. However, compounds 9, 14, 
and 19 were potent against S. aureus, S. agalactiae, and F. cloumnare. The 
structure-activity relationship (SAR) study revealed that antibacterial 
efficacy was significantly affected by the length of linker and imidazole 
substituted group. Amin et al. [32] reported the synthesis of novel 
series of 7-hydroxy-4-methylcoumarin and 7-alkoxy-4-methylcoumarin 
derivatives following Pechmann condensation process. The derivatives 
were investigated for their antimicrobial activity against S. aureus, 
Bacillus subtilis, E. coli, Pseudomonas aeruginosa bacterial strains, and 
antifungal activity against Candida albicans. The author concluded that 
derivatives bearing 7-hydroxy group exhibited better antimicrobial 
activity than those bearing 7-alkoxy group in the structure. Aziem 
et al. [33] synthesized 2,3-diyhdro-1,3,4-thiadiazoles, pyrazoles, and 
coumarin containing benzofuran derivatives following the approach of 
green chemistry and investigated for their antibacterial activity. Hamid 
and Kubba [34] reported the synthesis and antibacterial activity of 
Schiff bases, chalcones, hydrazones, and hydrazinyl thiazoles derivatives 
incorporated in 8-formyl-7-hydroxy-4-methyl coumarin derivatives. 
The results revealed that novel chalcones having a phenyl group in the 
structure represented excellent activity against Gram-negative bacterial 
strains. However, hydrazone and cyclized hydrazinyl thiazole derivatives 
exhibited good activity against Gram-positive bacterial strains.
Antitubercular activity
Tandon et al. [35] explored the anti-tuberculosis (TB) potential of 
a series of amino and acyl aminocoumarins against H37Rv strain. 
The analogs were also tested for their MBCs, fractional inhibitory 
concentration index values, and cytotoxicity. The minimal inhibitory 
concentrations (MICs) for a susceptible and a multidrug-resistant 
clinical isolate of Mycobacterium tuberculosis were also evaluated. 
Electron and fluorescence microscopy of the test compound-treated 
mycobacterial samples was also analyzed to find out the target site. 
7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; 
NA5) showed the lowest MIC of 1 mg/L against H37Rv strain. Reddy 
et al. [36] synthesized a series of coumarin-oxime ether using the SN2 
reaction of bromomethyl coumarins with butane-2,3-dione monoxime 
and the derivatives were tested for in vitro anti-TB activity against 
MTBH37Rv strain. The compound (1 h) was found to be the most active 
by exhibiting MIC of 0.04 μg/ml which is closer to the MIC value of 
standard drug isoniazid (0.02 μg/ml). The compound (1 h) was further 
used to explore the mode of interaction with a model serum protein, 
bovine serum albumin which displayed excellent interaction without 
influencing its normal functioning. Mangasuli et al. [37] synthesized 
a series of substituted C-4 bridged coumarin-theophylline hybrids 
and assayed for their anti-TB activity against M. tuberculosis H37Rv, 
antimicrobial activity against Gram-positive bacteria (S. aureus) and 
Gram-negative bacterial strains (E. coli, Salmonella typhi) as well as 
fungal strain (C. albicans). The compound (3a) represented remarkable 
Fig. 2: List of 4‑hydroxy and 7‑hydroxy coumarin derivatives synthesized by treating with activated aziridines
Fig. 3: A series of novel 1,2,4‑triazole (compounds 3‑6), 4,5‑dicyanoimidazole (compound 7) and Purine (compound 8‑13) coumarin 
derivatives and their acyclic nucleoside analogs 14‑18
Fig. 4: The structure of compound 22 and 67 exhibited potent 
inhibitory activity against tumor necrosis factor-α production
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anti-TB activity with MIC of 0.12 μg/ml. Compounds (3a, 3f) exhibited 
significant anti-microbial activity and 3a, 3b, and 3f revealed moderate 
antifungal activity. The structural analysis of synthesized compounds 
was accomplished using crystal X-ray diffraction technique, and 
molecular docking study against 4DQU enzyme of M. tuberculosis 
exhibited remarkable binding interactions.
Anticancer activity
Benci et al. [38] synthesized and investigated antitumoral 
potential of derivatives of novel 1,2,4-triazole (compounds 3–6), 
4,5-dicyanoimidazole (Compound 7) and purine (compound 8–13) 
coumarin derivatives and their acyclic nucleoside analogs (14–18) 
(Fig. 3). The results of antitumoral assays conducted on human 
tumor cell lines, communicated that compound 6 had moderate anti-
proliferative activity against the HeLa cell line (IC50: 35 μM), whereas 
compound 10 was moderately active against the HeLa (IC50: 33 μM), 
HepG2 (IC50: 25 μM), and SW620 (IC50: 35 μM) cell lines.
Cheng et al. [39] synthesized and explained SAR of various coumarin 
derivatives exhibiting tumor necrosis factor (TNF)-α inhibitory action. 
The compound 22 and 67 (Fig. 4) exhibited excellent TNF-α inhibitory 
action in human peripheral blood mononuclear cells triggered by 
bacterial lipopolysaccharide (LPS).
Lee et al. [40] synthesized a series of 7-diethylaminocoumarin 
derivatives and investigated for anti-proliferative action against human 
umbilical vein endothelial cell (HUVEC) and some other cancer cells. 
This research concluded that the cyano group at position-4 will elevate 
the biological efficacy. In particular, compounds 9 and 10 represented 
remarkable anti-proliferative activity against various cancer cell lines, 
and compounds 12 and 15 displayed commendable selectivity for 
HUVEC (Fig. 5). Hence, these analogs can be utilized as a prototype to 
develop novel non-toxic angiogenesis inhibitors and small molecular 
ligands to target HUVEC.
Chen et al. [41] isolated and characterized 2α,7β,20α-trihydroxy-3β,21-
dimethoxy-5-pregnene (1), 6,7,9α-trihydroxy-3,8,11α-trimethylcyclohexo-
[d, e]-coumarin (2), 3β-hydroxy-27-benzoyloxylup-20(29)-en-28-oic 
acid (3), and 3β-hydroxy-27-benzoyloxylup-20 (29)-en-28-oic acid methyl 
ester (4), along with 24 known compounds from the roots and aerial 
parts of Helicteres angustifolia (Sterculiaceae). The two-cucurbitacin 
derivatives, cucurbitacin D and J exhibited excellent anti-proliferative 
activities against hepatocellular carcinoma BEL-7402 cells and malignant 
melanoma SK-MEL-28 cells.
Nofal et al. [42] synthesized and investigated a series of novel 3-bromo-
4-methyl-7-methoxy-8-amino substituted coumarins and 2-substituted 
7-bromo-6-methyl-8H-pyrano-benzimidazoles, benzoxazoles, and/
or benzoxazine-8-ones against their cytotoxic potential. Out of the 
synthesized derivatives, the compound 15a (Fig. 6) represented 
remarkable antitumor activity against Ehrlich ascites carcinoma.
Lou et al. [43] reported for a novel coumarin, Juglans side C isolated from 
the bark of Juglans mandshurica. Juglans side C exhibited reasonable 
cytotoxicity against human hepatocellular carcinoma Hep3B cells 
(IC50 value: 70.9 μM). In addition, Annexin V-FITC/PI staining assay 
technique specified that significantly induced apoptosis in Hep3B cells. 
The study concluded that this plant could be an auspicious plant for the 
treatment of HCC and its findings could be explored in future research.
Tan et al. [44] synthesized and investigated a series of 8-ethoxy-3-
nitro-2H-chromene based HDACIs against K562, A549, MCF-7, PC3, 
and HeLa cancer cell lines. The research revealed that o-amino anilide 
and D-Phe substituted α-amino amide derivatives (16a and 16b) were 
more effective toward HADC1 over HADC2 and were moderated to 
weak active over HADC6. However, the amide ZBG analogs (12a and 
12b, 14 and 15) were only average HDAC6 inhibitors and were more 
active over HDAC1 and HDAC2. The o-aminoanilides 9b, 9c, 10b, 10c, 
11b, and α-aminoamides, 16a and 16b were effective against HADC1. 
The phenyl substituted o-aminoanilides 10b and 10c were more active 
than MS-275 as HADC1 inhibitors and more selective toward HADC2. 
Lv et al. [45] designed and synthesized a series of 2-phenylpyrimidine 
derived coumarin analogs bearing telomerase-inhibiting activity. 
These analogs were investigated for cytotoxic action against CNE2, 
KB, and Cal27 cancer cell lines. The results displayed that most of the 
Fig. 5: The structure of 7‑diethylaminocoumarin derivatives
Fig. 6: The structure of most active compound (15a) from novel 
3‑bromo‑4‑methyl‑7‑methoxy‑8‑amino substituted coumarins, 
benzoxazoles, and/or benzoxazine‑8‑ones
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compounds were effective in resisting tumor cell proliferation and 
concluded that compound 13 is a highly potent derivative that can 
inhibit CNE2 proliferation. The molecular docking studies revealed 
that compound 13 bonded through multiple interactions, including 
hydrogen bonding and hydrophobic interactions against telomerase 
reverse transcriptase. Yu et al. [46] designed and synthesized 34 new 
dihydroartemisinin-coumarin analogs, and these analogs represented 
remarkable cytotoxic activities against HT-29 and MDA-MB-231 cell 
lines, especially under hypoxia condition. The SAR study and docking 
analysis had shown that carbonic anhydrases IX was the main target of 
the hybrids. The results had shown that these compounds noticeably 
exhibited antiproliferative activity against HT-29 cell lines, by arresting 
G0/G1 phase of HT-29 cells, blocked the movement of tumor cells, 
and induced a great reduction in mitochondrial membrane potential. 
Batran and Kassem et al. [47] reported the synthesis of a novel series 
of 4-phenylcoumarin derivatives, and explored these compounds for 
anticancer activity against MCF-7 cell lines. Compounds 3a, 3b, and 3f 
represented the excellent cytotoxic effect on MCF-7 cell lines without 
producing any cytotoxic effect on human normal skin cell line (BJ-1). 
In addition, tubulin polymerization assay was also accomplished for 
the most potent compounds, i.e. 3a, 3b, and 3f. The results revealed 
that the three derivatives represented significant inhibitory activity 
of TUBb polymerization in comparison with standard drug colchicine 
(IC50=9.37, 2.89 and 6.13 μM, respectively, vs. 6.93 μM for colchicine). 
Compound 3a was further exposed to cellular mechanistic studies on 
MCF-7 cells and showed induction of apoptosis and cell cycle arrest 
at G2/M phase, along with its significant activation of caspase-7. 
The combined studies of molecular docking, pharmacophore 
hypothesis, and MD studies exposed remarkably information on the 
structural features of the molecules, which are essential to explore 
drug interactions and designing of the novel drug molecule. Emami 
et al. [48] synthesized a new series of 3-(4-aminothiazole-5-carbonyl)-
2Hchromen-2-ones,(3a-l) and (4a-c) with a cyclic amine, substituted 
cyclic amine, aniline or substituted aniline moieties, and investigated 
for cytotoxic potential employing MTT assay against MCF-7, HepG2, and 
SW400 cell lines. The thiomorpholine derivative (3k) was potent with 
(IC50 values: 7.5–16.9 μg/ml). The compound (3k), against MCF-7 cells 
represented apoptosis and ceased the cell proliferation at the G1-phase.
The analogs had significant effects for free radical scavenging activity 
and ferric-reducing power as evaluated by 2,2-diphenylpicrylhydrazyl 
(DPPH) and ferric reducing antioxidant power assay method. Singh 
et al. [49] designed and synthesized 28 novel triazolebound isatin-
coumarin hybrids, and investigated for antiproliferative potential 
against human cancer cell lines of THP-1, COLO-205, HCT-116, and 
PC-3 and compounds A1 to A6, B1 to B4, and C1 to C3 had prodigious 
inhibitory action against THP-1, COLO-205, and HCT-116 cell lines. The 
SAR study expressed that the cytotoxic activity rely on substitution 
on isatin and the length of carbon-bridge linking isatin moiety with 
triazole moiety. Two carbon-bridge and unsubstituted isatin were 
found to be essential for cytotoxicity. Three most potent hybrids (A1, 
A2, andB1) were also evaluated for tubulin polymerization inhibition 
activity and compound (A1) was found to be most potent with IC50 
value of 1.06 μM. Zhou et al. [50] designed and synthesized 5 new 
analogs of phenylsulfonylfuroxan joined with 3-benzyl coumarin 
and their seco-B-ring derivatives (2–6). The compound 3 was highly 
active anti-cancer agent with IC50 values ranging from 0.5 nM to 
143 nM against 9 drug-sensitive and 4 drug-resistant cancer cell lines. 
Compound 3 induced the early apoptosis and hardly affected the cell 
cycle of A2780. Xiang et al. [51] rationally optimized a series of3-aryl-4-
aniline/aryloxy-2H-chromen-2-one derivatives using structure-based 
modification of leadcompound LE-18d to obtain a multifunctional 
effect against ERα and VEGFR-2. By means ofbioisosteric replacement, 
F atom was incorporated to C-4’ position of 3-phenyl substituent 
while, O atom was substituted to the 4-position of coumarin moiety, 
for anticipated interactions with essential amino acid residues of 
targeted ERα receptor and VEGFR-2 enzyme. Among these derivatives, 
O-linked compounds represented potent ER-α binding affinities and 
antiproliferative potential against cancer cells and angiogenesis-
related cells. Further investigation exposed that (42d) was able to 
inhibit MCF-7 cell migration and arrest cell cycle at G0/G1 phase in 
MCF-7 cells in a concentration-dependent manner. Furthermore, a 
significant anti-estrogenic property observed in RT-PCR, and (42d), 
inhibited the activation of VEGFR-2 and the signaling transduction of 
Raf-1/MAPK/ERK pathway in MCF-7 cells. Molecular docking analysis 
of (42d) presented ER-α binding mode embodying three essential 
hydrogen-bonding interactions, which is the characteristic character 
of selective estrogen receptor modulator. Bu et al. [52] synthesized 
and characterized a chain of novel 5a, 8a-epidioxyandrost-3b-ol-17-
(O-phenylacetamide) oxime derivatives (9a-o). These analogs were 
investigated for their anti-proliferative activities against human 
hepatocellular carcinoma cells (HepG2, Sk-Hep1) and human breast 
cancer cells (MCF-7, MDAMB231). The compounds 9d, 9f, 9h, 9j, and 
9m exhibited significant anti-proliferative activity with IC50<20 µM). 
Moreover, coumarin-9d conjugate (12) localized in mitochondria, 
leading to higher anticancer activities over the lead moiety, which was 
confirmed by a fluorescence imaging technique.
Antimicrobial activity
Al-Haiza et al. [53] synthesized Pyrimidino [5`,4`-6,5]-pyridino[3`,2`-
6,5]-and pyrrolo[3`,2`-5,6]4H-pyrano-[3,2-c][1]benzopyran-6-one 
derivatives (5-7 and 10) by reacting 2-amino-4-(p-bromophenyl)-3-
cyano(carboethoxy)-4H,5H-pyrano[3,2-c][1]benzopyran-5-ones(3a,b)
with a variety of reagents (Fig. 7). Alkylation of (3b) with either 2-furoyl 
chloride or chloroacetyl chloride produced 2-N-substituted derivatives 
(9a, b). Benzofurano [3,2-b] 4H-pyran derivative (12) was also prepared 
and investigated for antimicrobial activity.
López-Rojas et al. [54] synthesized a novel series of 26 compounds 
having coumarin-1,2,3-triazole conjugates with varied alkyl, phenyl, 
and heterocycle moieties at C-4 of the triazole nucleus using a 
copper(I)-catalyzed, Huisgen 1,3-dipolar cycloaddition reaction. Out 
of these analogs 6 compounds exhibited remarkable antibacterial 
activity against Enterococcus faecalis (MIC: 12.5-50µg/ml) based 
on their MICs against a selected microorganism. Furthermore, 
these compounds represented comparatively minimal toxicity 
against human erythrocytes. Tiwari et al. [55] synthesized 15 novels 
3-((dicyclohexylamino)(substitutedphenyl/heteryl)-methyl)-4-
hydroxy-2H-chromen-2-onederivatives (4a-o) under solvent-free 
Fig. 7: The structure of 2‑amino‑4‑(p‑bromophenyl)‑3‑
cyano(carboethoxy)-4H,5H-pyrano[3,2-c][1]benzopyran-5-ones 
(3a,3b)
Fig. 8: The structure of (+)‑12‑oxocanolide and canolide A
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condition using the ionic liquid [Et3NH][HSO4] as a catalyst which 
was further characterized by IR, 1H-NMR, 13C-NMR, and mass spectral 
analysis. All the analogs were investigated for their antifungal and 
antibacterial efficacy, the results revealed that the compound (4k) was 
potent antifungal and the compound (4e) was potent antibacterial 
agent. The compound (4k) acts by inhibition of ergosterol biosynthesis 
in C. albicans that was confirmed using an ergosterol extraction and 
quantitation assay technique. The most active compounds 4e and 4k 
were non-cytotoxic against human cancer cell line HeLa.
Anti‑HIV activity
Kostova et al. [56] presented the SAR of various synthetic coumarin 
derivatives used as an anti-HIV agent (Fig. 8). These were accomplished 
as reverse transcriptase inhibitors, protease inhibitor, and integrase 
inhibitors. Jashari et al. [57] developed an improved synthetic scheme 
in which 4-chlorocoumarin-3-sulfonyl chloride (4) was synthesized in 
excellent yield (Fig. 9). The synthesized compound 4-chlorocoumarin-
3-sulfonyl chloride (4) was further reacted with 2-aminopyridines 
and 2-aminothiazoles to yield substituted pyrido and thiazino-1,2,4-
thiadiazino-benzopyranone dioxides (a potential anticancer and anti-
HIV agents).
Antioxidant activity
Majumdar et al. [58] evaluated in vitro antioxidant potential and 
inhibition of α-amylase and α-glucosidase activities of methanolic 
extracts of leaves of few Indian medicinal plants. The antioxidant 
activities of the samples were measured by two different methods 
while the Folin–Ciocalteu reagent assay was used to estimate 
the phenolic contents of extracts. Methanolic extracts from dried 
leaves of Phyllanthus emblica, Cajanus cajan, Cannabis indica, and 
Formica pratensis were prepared. DPPH radical scavenging and iron 
chelating methods estimated antioxidant activities. The inhibitions 
of carbohydrate-hydrolyzing key enzymes, for example, α-amylase 
and α-glucosidase activities were assayed. Acarbose was used as a 
reference compound in both of assay procedures. Goudgaon et al. [59] 
developed that the reaction of synthon 3-acetyl-2H-chromen-2-one (1)
with 3-substituted aryl-1-phenylpyrazol carboxaldehyde (2a-d) gave 
intermediate compounds 3-[3-(3-substituted aryl-1-phenylpyrazol-4-
Fig. 9: The structure of 4‑chlorocoumarin‑3‑sulfonyl chloride (4)
Fig. 10: The structure of novel coumarin‑3‑carboxamides and 
their hybrids with the alpha‑lipoic acid
Fig. 11: The structure of 4‑methyl‑7‑hydroxycoumarin
Fig. 12: The structure of 3-hydroxy-β-lapachone 4 with ylide 5 
gave the coumarin derivative 7a
Fig. 13: The structure of the series of 7-methoxy-4-methyl-8-[5-
(substituted aryl) isoxazol-3-yl]–2H–benzopyran-2-ones
Fig. 14: The structure of novel coumarin derivatives with a 
7‑azomethine linkage
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yl)acryloyl]-2H-chromen-2-ones (3a-d). These chalcones on cyclization 
with thiourea produced desired target compounds (4a-d). These 
compounds were investigated for their antimicrobial and antioxidant 
activities. Melagraki et al. [60] designed and synthesized a series of 
novel coumarin-3-carboxamides and their hybrids with the alpha-lipoic 
acid. The synthesized compounds were evaluated for their antioxidant 
activity to inhibit in vitro lipoxygenase and in vivo anti-inflammatory 
activity (Fig. 10).
Singh et al. [61] studied and described the kinetics and the transient 
absorption spectra from the reactions of•OH, O•−, e−aq, and SO4•−radicals 
with coumarin, 4-methyl-7-hydroxycoumarin, 7-methoxycoumarin, 
and 6,7-dimethoxycoumarin in aqueous solutions by pulse radiolysis 
with optical detection (Fig. 11).
Beillerot et al. [62] synthesized and evaluated the protective effects of 
coumarin derivatives against oxidative stress induced by doxorubicin 
(DOX). 4-Methyl-7,8-dihydroxycoumarin represented excellent 
antioxidant potential, less cytotoxicity and could decrease reactive 
oxygen species (ROS) production generated by DOX without affecting 
DOX toxicity in MCF7 cells.
Anti‑inflammatory activity
Nicolaides et al. [63] synthesized 3-hydroxy-β-lapachone (4) with 
ylide (5) gave the coumarin derivative (7a), which was transformed 
to compounds (10–14). Compound 14 was then converted to benzo[f]
seselin (15) as well as to benzo[l]khel lactones 16, 18 from which the 
targeted compounds 17, 19I, 19II, 20, 21I, and 21II were synthesized 
(Fig. 12). All the compounds were interacted with DPPH in a 
concentration and time-dependent manner. All the compounds were 
highly active against the soybean lipoxygenase, whereas compounds 
12, 17, and 19II significantly compete with dimethylsulfoxide (DMSO) 
for •OH. Compounds 7a, 7b, 12, and 17 showed 48.7–58.9% anti-
inflammatory activity against carrageenin-induced rat paw edema.
Sreeja et al. [64] reported the in silico molecular modifications of 
proposed derivatives using different software. The five analogs were 
shortlisted for the synthesis with the help of selection parameters 
and were synthesized by conventional and microwave assisted 
synthetic methods. The synthesized compounds were subjected to 
pharmacological screening such as acute toxicity study, analgesic 
activity, and anti-inflammatory activity by carrageenan-induced rat 
paw edema method. Gummudavelly et al. [65] synthesized a new 
series of 7–methoxy-4-methyl-8-[5-(substituted aryl)isoxazol-3-yl]-2H-
benzopyran-2-ones by cyclization of chalcones, 8–(2-substituted prop-2-
ene)-7-methoxy-4-methyl-2H-benzopyran-2-ones with hydroxylamine 
hydrochloride (Fig. 13). The synthesized compounds were investigated 
for their antimicrobial and anti-inflammatory activities and some of 
them exhibited significant activity.
Nicolaides et al. [66] synthesized a series of novel coumarin derivatives 
with a 7-azomethine linkage starting from 7-formylcoumarin (Fig. 14). 
The compounds were tested in vivo for their anti-inflammatory and 
in vitro for antioxidant potential. Compounds (3a) and (3e) displayed 
significant anti-inflammatory action against carrageenan-induced rat 
paw edema.
Chen et al. [67] designed and synthesized a series of new phenyl-
pyrazoline-coumarin derivatives (4a-4m). All of the compounds had 
been assayed for their anti-inflammatory activity using carrageenan-
induced paw edema technique for evaluating their inhibition against 
LPS-induced IL-6 release. The compound (4m) was potent anti-
inflammatory agent resulted in inhibiting IL-6, TNF-α, and nitric 
oxide (NO) production. In addition, the compound (4m) significantly 
suppressed the expressions of nitric oxide synthase, cyclooxygenase-2 
and the productions of IL-6, TNF-α, NO through NF-ҡB/MAPK signaling 
pathway. Moreover, in vivo studies revealed that compound (4m) 
could inhibit AA-induced rat ankle joints. Yong Jiang et al. [68] isolated 
three new prenylated phenylpropenols, exotiacetals A-C (1-3), 10 new 
coumarin derivatives, exotimarins A-I (4-13), and 35 known analogs 
(14-48) from the roots of Murraya exotica. The absolute configurations 
of the new compounds were characterized through comparison of 
their specific rotations, single-crystal X-ray diffraction data, Mosher’s 
method, the ECD exciton coupling method, comparison of experimental 
and calculated ECD data, and the ECD data of the in situ formed 
transition metal complexes. Compounds 1-3 were biosynthesized from 
two prenylated p-coumaryl alcohol moieties through Diels-Alder [4+2] 
cycloaddition and cyclic hemiacetal formation reactions creating a 
unique hexahydro-1H-isochromen-1-ol system. Compounds1, 28, 33, 
and 35 demonstrated inhibition against LPS-induced NO production in 
BV-2 microglial cells with IC50 values of 8.6 ± 0.3, 11.8± 0.9, 15.5 ± 0.9, 
and 16.9 ± 1.0 μM, respectively.
Antipyretic activity and analgesic activity
Keri et al. [69] synthesized a series of 4-[4-(6-phenyl-pyrimidin-
4-yl)-phenoxymethyl]-chromen-2-ones [5-7(a-e)] from various 
4-bromomethyl coumarins 1(a-e) (Fig. 15). The synthesized compounds 
were screened for analgesic and antipyretic activities at a dose of 25 
and 100 mg/kg, body weight, respectively. The compounds 5 (d), 
6 (c), and 7 (d) represented significant analgesic activity comparable 
with standard drug Analgin using Tail-flick model. Compounds 5 
(a) and 7 (a-d) exhibited significant anti-pyretic activities comparable 
with standard drug aspirin using yeast induced pyrexia model. QSAR 
Fig. 15: The structure of novel series of 4-[4-(6-phenyl-pyrimidin-
4-yl)-phenoxymethyl]-chromen-2-ones [5-7(a-e)] from various 
4‑bromomethyl coumarins 1(a‑e)
Fig. 16: The structure of coumarin analogs with phenylpiperazine
34
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 27-38
 Gupta et al. 
studies concluded that compounds with 2-amino group of pyrimidine 
ring increase analgesic and antipyretic activities and compounds with 
2-hydroxyl and 2-thio group of the pyrimidine ring improves DNA 
cleavage activities.
Anti‑Alzheimer’s activity
Zhou et al. [70] designed and synthesized three series (A-C) of coumarin 
analogs by substitution with phenylpiperazine and investigated against 
Alzheimer’s disease (AD) (Fig. 16). The anticholinesterase activities of 
these compounds were also evaluated according to Ellman’s method 
against freshly prepared acetylcholinesterase (AChE) using donepezil 
as the standard drug.
Costas-Lago et al. [71] synthesized a series of novel compounds of 
hybrid structure pyridazine-coumarin through a multistep approach 
based on Knoevenagel reaction using as key intermediate pyridazinone 
16 as potent, selective, and reversible inhibitors of monoamine oxidase 
B (MAO-B). Compounds 9b and 9d are the most potent compounds 
with IC50 values of 0.75±0.17 μM and 0.56±0.04 μM, respectively, and 
lack of cytotoxic effects. Liang et al. [72] designed and synthesized a 
novel series of coumarin-dithiocarbamate hybrids for the treatment 
of AD. The compound 4n was found to inhibit AChE (IC50: 0.027 μM 
for hAChE) and good inhibition of Ab aggregation (40.19% at 25 μM). 
The compound (4n) could interact with the catalytic active site and 
peripheral anionic site of AChE determined by kinetic and molecular 
modeling studies. However, compound 4n exhibited remarkable blood–
brain barrier permeability, specific metal-chelating property, and low 
toxicity in SH-SY5Y neuroblastoma cells. Furthermore, compound 
4n could reverse the cognitive dysfunction of scopolamine-induced 
AD mice and did not exhibit any acute toxicity in mice at doses up to 
1000 mg/kg. Its excellent in vitro and in vivo profiles proclaimed it 
as a potential lead molecule to treat AD. Xie et al. [73] designed and 
synthesized novel hybrids by combining N-benzyl pyridinium moiety 
and coumarin, with ChE and MAO-B inhibitory activities. Most of the 
compounds exhibited excellent inhibitory activity for ChE and Aβ (1-42) 
self-aggregation and selectively inhibition to MAO-B over MAO-A. The 
compound(7f) showed excellent inhibitory action against hMAO-B, and 
balanced inhibitory action for ChEs and hMAO-B (2.32 μM for eqBuChE; 
1.57μM for hMAO-B; 0.0373 μM for eeAChE). The compound 7f was 
found to be a mixed-type inhibitor, which interacts simultaneously to 
CAS and PAS of AChE, determined by molecular modeling and kinetic 
studies and it was a competitive inhibitor for the active site of MAO-B. 
Furthermore, compound 7f with lack of toxicity on PC12 neuroblastoma 
cells exhibited good ability to inhibit Aβ (1-42) self-aggregation and 
cross the blood–brain barrier. Kong et al. [74] designed and synthesized 
a series of coumarin-pargyline hybrids (4a-x) and screened as novel dual 
inhibitors of AD. Most of the compounds revealed an excellent ability to 
inhibit amyloid-β (Aβ) aggregation and monoamine oxidases. Especially, 
compound (×4) exhibited significant inhibitory actions against 
monoamine oxidases (IC50, 3.275±0.040 μM for MAO-A;0.027±0.004 μM 
for MAO-B) and Aβ1-42 aggregation (54.0±1.1%, 25 μM). Furthermore, 
compound (×4) showed low toxicity estimated by in vitro cell toxicity 
test and good blood–brain barrier permeability. These results revealed 
that compound (×4) was an effective and an auspicious candidate for 
Alzheimer’s. Khoobi et al. [75] synthesized a novel series of coumarin-
lipoic acid hybrids through cycloaddition click reaction and evaluated 
them for the treatment of AD. All the compounds were investigated for 
their neuroprotective and cholinesterase inhibitory activities. Among 
them, compound (11) which was found to be the most potent AChE 
inhibitor, exhibited the excellent inhibitory effect on intracellular ROS 
formation, and β-aggregation, as well as the ability of selective bio-
metal chelation and neuroprotection against H2O2 and β1-42-induced 
cytotoxicity. Collectively, this result indicated that the compound (11) 
was a promising lead compound with desired multifunctional properties, 
in the treatment of AD. Baruah et al. [76] evaluated the inhibitory 
efficacy of two substituted coumarin derivatives on neuroprotective and 
cholinesterase inhibitory activities in the presence of human SA. The 
experimental results indicated the inhibition to be of noncompetitive 
type with both the systems showing substantial inhibitory activity on 
AChE. The compound chromenyl coumarate was found to be a potent 
inhibitor (IC50: 48.49±5.6 nM. These results revealed that the compound 
was an effective and auspicious candidate for AD. Akbarzadeh 
et al. [77] designed and synthesized a new series of coumarin-pyridinium 
hybrids as novel dual inhibitors of AD. The synthesized compounds were 
evaluated for anti-butyrylcholinesterase and anti-acetylcholinesterase 
using Ellman’s method. Among synthesized derivatives, the compounds 
(7l) were found to be the most active compound toward AChE (IC50: 10.14 
mM), 7g and 7h exhibited highest BChE inhibitory activity (IC50: 0.32 and 
0.43 mM, respectively). Among them, the compound 7g selectively bound 
to BChE with SI of 101.18. The kinetic study of the compounds 7g and 7l 
revealed that they were mixed type inhibitor for both AChE and BChE. In 
addition, they showed low inhibitory activity against β-secretase.
Anticoagulant activity
Manolov et al. [78] synthesized 4-hydroxycoumarin derivatives. The X-ray 
crystallography analysis of 3,3′-(2,3,4-trimethoxyphenylmethylene) 
bis-(4-hydroxy-2H-1-benzopyran-2-one) (7) and 3,3′-(3,5-imethoxy-
Fig. 17: The structure of 3,3′-(4-chlorCophenylmethylene)bi
s‑(4‑hydroxy‑2H‑1‑benzopyran‑2‑one) (12)
Fig. 18: The structure of the series of coumarin‑3‑acyl derivatives
Fig. 19: The structure of 5,7‑dimethoxy‑8‑(3’‑hydroxy‑
3’methyl‑1’‑butene)‑coumarin
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4-hydroxyphenylmethylene) bis-(4-hydroxy-2H-1-benzopyran-2-one) 
(9) confirmed the structure of these compounds and a comparative 
pharmacological study of the anticoagulant effect with respect to warfarin 
showed that the synthesized compounds have good anticoagulant 
activities. The most active compound is 3,3′-(4-chlorophenylmethylene) 
bis-(4-hydroxy-2H-1-benzopyran-2-one) (12) with low toxicity, very 
good index of absorption and dose-dependent anticoagulant potential 
(Fig. 17).
Antiparkinsonism activity
Chimenti et al. [79] synthesized a series of coumarin-3-acyl derivatives 
and screened for their selective inhibitory potential against monoamine 
oxidases (Fig. 18). The coumarin-3-carboxylic acids (2a-e) showed 
selective, reversible inhibitory activity against MAO-B isoform. The 
compound (2a) exhibited pIC50 7.76, and a selectivity index (pS.I.) 2.94 
and the compound (2b)represented pIC50 7.72 and a pS.I. of 2.80. The 
compounds (3a-e) exhibited high pIC50 values against both MAO-A 
and MAO-B isoforms; however, compound (3d) represented excellent 
potential against MAO-B with a pIC50 value of 8.00.
Antimalarial activity
Oketch-Rabah et al. [80] isolated a new antiplasmodial coumarin, 
5,7-dimethoxy-8-(3’-hydroxy-3’methyl-1’-butene)-coumarin from the 
roots of Toddalia asiatica (Fig. 19), revealing its traditional use to treat 
malaria.
Himangini et al. [81] synthesized coumarin-pyrazoline hybrids and 
investigated them as an anti-malarial agent against chloroquine-
sensitive (MRC-02) and chloroquine-resistant (RKL-2) strain of 
Plasmodium falciparum and Plasmodium berghei malaria. The most 
active antimalarial compound was 3-(1-benzoyl-5-(4-flurophenyl)-
4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-
one (IC50: 4.21 mg/ml) and it provided complete protection to the 
infected mice at 24 mg/kg for 4 days. Awasthi et al. [82] synthesized 
22 coumarin-triazole derivatives by alkylation of 7-hydroxy-4-
methyl coumarin followed by click chemistry at seventh-position. 
The synthesized compounds were investigated for antiplasmodial 
activity against chloroquine sensitive strain of P. falciparum (3D7) and 
compound 9 was found to be the most potent molecule with IC50 value 
of 0.763 ±0.0124 μg/ml.
Anticonvulsant activity
Siddiqui et al. [83] synthesized multiple coumarin derivatives of 
heteroaryl semicarbazones by the reaction of heteroaryl hydrazine 
carboxamide with aryl aldehydes or ketones (Fig. 20). The analogs were 
tested for their anticonvulsant activity employing pentylenetetrazole-
induced seizure, and maximal electroshock seizure tests at 30, 100, 
and 300 mg/kg dose levels along with the study of neurotoxicological 
indications. Three compounds having 3,4-Cl.C6H3, 2-OCH3.C6H4, and 
4-Br.C6H4 represented highest anticonvulsant activity at a dose of 
30 mg/kg, as compared with phenytoin.
Anti‑hyperlipidemic activity
Sashidhara et al. [84] designed and synthesized derivatives bearing 
both coumarin and indole moieties in a single molecule (Fig. 21) by the 
Duff reaction on naphthalene-1-ol, which was engaged in a Knoevenagel 
type reaction with appropriate active methylene compounds and tested 
them for hypolipidemic activity. These coumarin aldehyde derivatives 
were further electrophilically substituted with suitable indoles 
using iodine in acetonitrile to produce coumarin bis-indole analogs. 
Similarly, another series of coumarin bis-indole analogs were also 
synthesized starting from 2-sec-butylphenol to synthesize another set 
of coumarin bis-indole analogs. These derivatives were investigated 
for hypolipidemic activity in the hyperlipidemic hamster model. In 
both the series of compounds, as far as coumarin, a pharmacophore 
is focused, the derivatives bearing substitution at position three plays 
a key role, and the presence of ethyl ester over methyl is preferred 
for profound activity. However, it was noticed that unsubstituted 
indoles have a good activity profile compared to substituted indoles. 
Among 12 tested compounds, the one bearing R=-C2H5 and R1=R2=-H 
exhibited lower plasma triglyceride levels by 55%, total cholesterol 
(TC) by 20%, accompanied by an elevation in HDL-C/TC ratio by 42% 
in hyperlipidemic rats to a maximum extent than some of the reference 
statins.
Tyrosinase inhibitor activity
Fais et al. [85] resynthesized coumarin-resveratrol hybrids by a 
traditional Perkin reaction carried out in refluxing DMSO between 
o-hydroxybenzaldehydes (or their methoxy substituted derivatives) 
and the corresponding aryl acetic acids, using dicyclohexylcarbodiimide 
as dehydrating agent to investigate the SAR (Fig. 22). Tyrosinase 
activity assays were accomplished with L-DOPA as substrate with little 
modifications and activity of mushroom tyrosinase was evaluated by 
spectrophotometric technique. IC50 values represented that these analogs 
Fig. 20: The structure of heteroaryl semicarbazones synthesized 
by the reaction of heteroaryl hydrazine carboxamide with aryl 
aldehydes or ketones
Fig. 21: The structure of a series of novel compounds that have 
both coumarin and indole entities
Fig. 22: The structure of coumarin‑resveratrol hybrids
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exhibited tyrosinase inhibitory activity. 3-(3,4,5-trihydroxyphenyl)-6,8-
dihydroxycoumarin was the most potent compound (IC50: 0.27 mM) 
than umbelliferone (IC50: 0.42 mM). The kinetic studies discovered that 
the compound resulted in non-competitive inhibition of tyrosinase and 
the number and position of free hydroxyl groups play a key role in the 
biological activity.
Antiobesity activity
Singh et al. [86] synthesized novel coumarin-dihydro quinazolinone 
analogs and investigated for agonist activity at GPR109a receptor. 
A compound 10c exhibited robust agonist activity at GPR109a with 
EC50 <11 nM. The homology model of human GPR109a protein was 
assayed to explore the binding capacity of the active molecule with 
the active site of GPR109a. Further, it was discovered that compound 
10c resulted in minimization of body weight in diet-induced obese 
mice model and reduced leptin in blood plasma and total serum 
cholesterol.
Antidiabetic activity
Lu et al. [87] synthesized 4flavonoid-coumarin analogs using natural 
8-(6”-umbelliferyl)-apigenin as a lead moiety and screened for their 
α-glucosidase inhibitory and glucose consumption promoting activity. 
The SAR studies revealed that C8/C7-C6” and C6/C5-C6” analogs 
improved α-glucosidase inhibition as compared with their flavone 
and coumarin lead structures. Compounds (5a) and (14a) were 
recognized as new α-glucosidase and α-amylase dual inhibitors similar 
to acarbose. Furthermore, compounds (5a) and (14a) exhibited glucose 
consumption-promoting activity in insulin-resistant and non-insulin 
resistant HepG2 cells models. Therefore, compounds (5a) and (14a) 
could be potential drug candidates for drug design to treat diabetes 
mellitus. Saeed et al. [88] designed and synthesized three series of 
diamine-bridged bis-coumarinyl oxadiazole hybrids by one-pot multi-
component technique. The synthesized conjugates (4a-j, 5a-j, and 
6a-j) were screened for potential inhibitory activity on α-glucosidase 
enzyme. Compound (6f) was used as the lead molecule that selectively 
inhibits the α-glucosidase enzyme (IC50 value: 6f of 0.07 ± 0.001 μM). 
This inhibition value was approximately 545-fold higher compared to 
the standard drug. Compound 6f was also appeared as the lead molecule 
with good inhibition strength (IC50: 0.04±0.02 μM) against intestinal 
maltase-glucoamylase. Against β-glucosidase enzyme, compound (6g) 
was emerged as the lead inhibitor with an IC50 value of 0.08±0.002 μM. 
Michaelis-Menten kinetic experiments were performed to explore the 
mechanism of inhibition. Molecular docking studies of the synthesized 
compounds were accomplished against glucosidase enzyme to explore 
ligand-protein interactions at the molecular level.
CONCLUSION
Coumarins and its analogs obtained from either natural or synthetic 
sources exhibited vital biological potential. The key role of coumarin 
derivatives in plants and animal biology has not been explored until 
now. The study of novel approaches employed to design and synthesize 
coumarin analogs bearing essential biological activities along with 
the study of SAR in addition to the proposed mechanism of action 
is incorporated in this review. Therefore, this review will help the 
researchers to design novel coumarin analogs by careful understanding 
of SAR studies incorporated in this review.
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